Grau E, Fontcuberta J, Pagés M A, Martinez R, Félez J, Net A, Rutllant M L
Angiology. 1986 Nov;37(11):832-9. doi: 10.1177/000331978603701107.
This study assessed the short-term effects of thrombolytic treatment in 38 patients with massive pulmonary embolism. Thirty-two were treated with streptokinase and six with urokinase. Intrapulmonary artery instillation of fibrinolytic agents was utilized except in 3 patients. There was a marked hemodynamic and arteriographic improvement (p less than 0.0005) in 33 patients (86.8%). Four patients (10.5%) died because of treatment failure. In these cases the fibrinogen concentration remained above 1 gr/liter during therapy. Bleeding was detected in 22 patients (57.8%) but was most often related to puncture or cut-down sites, and only 2 patients (5.2%) had major bleeding. One patient (2.6%) had cerebral hemorrhage. It is concluded that "classic" thrombolytic treatment is to be chosen in life-threatening pulmonary embolism. However, the difficulties sometimes encountered in producing an intense lytic effect and its low fibrinolytic specificity for the thrombus do not permit the obtainment of better results.
本研究评估了38例大面积肺栓塞患者接受溶栓治疗的短期效果。32例接受链激酶治疗,6例接受尿激酶治疗。除3例患者外,均采用肺动脉内注入纤溶药物。33例患者(86.8%)出现明显的血流动力学和血管造影改善(p<0.0005)。4例患者(10.5%)因治疗失败死亡。在这些病例中,治疗期间纤维蛋白原浓度保持在1g/L以上。22例患者(57.8%)出现出血,但大多与穿刺或切开部位有关,仅有2例患者(5.2%)发生大出血。1例患者(2.6%)发生脑出血。结论是,在危及生命的肺栓塞中应选择“经典”溶栓治疗。然而,有时在产生强烈溶栓效果方面遇到的困难及其对血栓的低纤溶特异性不允许获得更好的结果。